The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.
本公开涉及 SHP2 的
抑制剂,例如
吡嗪化合物,以及它们在治疗与 SHP2 调节相关的疾病中的用途,例如努南综合征、豹综合征、幼年骨髓单核细胞白血病、神经母细胞瘤、
黑色素瘤、急性髓性白血病以及乳腺癌、肺癌和结肠癌。还公开了包含上述成分的药物组合物。